Medicare begins coverage for specific GLP-1 weight-loss medications on July 1, 2026. This expansion provides millions of eligible seniors access to treatments such as Novo Nordisk's Wegovy.
Clinical data shows semaglutide (Wegovy) reduces risks of heart and kidney complications. These benefits specifically address health concerns prevalent within the Medicare population.
The coverage expansion serves as a major volume catalyst for Novo Nordisk’s weight-loss franchise. However, the company anticipates potential increases in pricing pressure.